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Introduction
In response to a request for proposal from the American
College of Rheumatology (ACR), our group was charged
with developing nonpharmacologic and pharmacologic
guidelines for treatments in gout that are safe and effective,
i.e., with an acceptable risk/benefit ratio. These guidelines
for the management and antiinflammatory prophylaxis of
acute attacks of gouty arthritis complement our article on
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guidelines to treat hyperuricemia in patients with evi-
dence of gout (or gouty arthritis) (1).
Gout is the most common cause of inflammatory arthri-
tis in adults in the US. Clinical manifestations in joints
and bursa are superimposed on local tissue deposition of
monosodium urate crystals. Acute gout characteristically
presents as a self-limited attack of synovitis (also called
“gout flare”). Acute gout attacks account for a major com-
ponent of the reported decreased health-related quality of
life in patients with gout (2,3). Acute gout attacks can be
debilitating and are associated with decreased work pro-
ductivity (4,5).
Urate-lowering therapy (ULT) is a cornerstone in the
management of gout (1) and, when effective in lowering
serum urate, is associated with a decreased risk of acute
gouty attacks (6). However, during the initial phase of
ULT, there is an early increase in acute gout attacks, which
has been hypothesized due to remodeling of articular urate
crystal deposits as a result of rapid and substantial lower-
ing of ambient urate concentrations (7). Acute gout attacks
attributable to the initiation of ULT may contribute to
nonadherence in long-term gout treatment, as reported in
recent studies (8).
In order to systematically evaluate management of acute
gouty arthritis, we generated multifaceted case scenarios
to elucidate decision making based primarily on clinical
and laboratory test–based data that can be obtained from a
gout patient by both nonspecialist and specialist health
care providers in an office practice setting. This effort was
not intended to create a novel classification system of gout
or new gout diagnostic criteria, since such endeavors are
beyond the scope of this work.
Prior gout recommendations and guidelines, at the in-
dependent (i.e., non–pharmaceutical industry sponsored)
national or multinational rheumatology society level, have
Significance & Innovations
● An acute gouty arthritis attack should be treated
with pharmacologic therapy, initiated within 24
hours of onset.
● Established pharmacologic urate-lowering therapy
should be continued, without interruption, during
an acute attack of gout.
● Nonsteroidal antiinflammatory drugs (NSAIDs),
corticosteroids, or oral colchicine are appropriate
first-line options for treatment of acute gout, and
certain combinations can be employed for severe
or refractory attacks.
● Pharmacologic antiinflammatory prophylaxis is
recommended for all gout patients when pharma-
cologic urate lowering is initiated, and should be
continued if there is any clinical evidence of con-
tinuing gout disease activity and/or the serum
urate target has not yet been achieved.
● Oral colchicine is an appropriate first-line gout
attack prophylaxis therapy, including with appro-
priate dose adjustment in chronic kidney disease
and for drug interactions, unless there is a lack of
tolerance or medical contraindication.
● Low-dose NSAID therapy is an appropriate choice
for first-line gout attack prophylaxis, unless there
is a lack of tolerance or medical contraindication.
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been published by the European League Against Rheuma-
tism (EULAR) (9,10), the Dutch College of General Practi-
tioners (11), and the British Society for Rheumatology
(BSR) (12). The ACR requested new guidelines in view of
the increasing prevalence of gout (13), the clinical com-
plexity of management of gouty arthritis imposed by
comorbidities common in patients with gout (14), and
increasing numbers of treatment options via clinical de-
velopment of agents (15–17). The ACR charged us to de-
velop these guidelines to be useful for both rheumatolo-
gists and other health care providers on an international
level. As such, this process and resultant recommenda-
tions involved a diverse and international panel of experts.
In this article, we concentrate on 2 of the 4 gout domains
(1) that the ACR requested for evaluation of pharmacologic
and nonpharmacologic management approaches: analge-
sic and antiinflammatory management of acute attacks of
gouty arthritis and pharmacologic antiinflammatory pro-
phylaxis of acute attacks of gouty arthritis. Part 1 of the
guidelines focused on systematic nonpharmacologic mea-
sures (patient education, diet and lifestyle choices, iden-
tification and management of comorbidities) that impact
hyperuricemia, and made recommendations on pharmaco-
logic ULT in a range of case scenarios of patients with
disease activity manifested by acute and chronic forms of
gouty arthritis, including chronic tophaceous gouty ar-
thropathy (1). Each individual and specific statement is
designated as a “recommendation,” in order to reflect the
nonprescriptive nature of decision making for the hypo-
thetical clinical scenarios.
So that the voting panel could focus on gout treatment
decisions, a number of key assumptions were made, as
described in part 1 of the guidelines (1). Importantly, each
proposed recommendation assumed that correct diagnoses
of gout and acute gouty arthritis attacks had been made for
the voting scenario in question. For treatment purposes,
it was also assumed that treating clinicians were com-
petent, and considered underlying medical comorbidities
(including diabetes mellitus, gastrointestinal disease,
hypertension, and hepatic, cardiac, and renal disease)
and potential drug toxicities and drug–drug interactions
when making both treatment choices and dosing deci-
sions on chosen pharmacologic interventions. The RAND/
University of California at Los Angeles (UCLA) methodol-
ogy used here emphasizes the level of evidence, safety,
and quality of therapy, and excludes analyses of societal
cost of health care. As such, the ACR gout guidelines are
designed to reflect best practice, supported either by level
of evidence or consensus-based decision making. These
guidelines cannot substitute for individualized direct as-
sessment of the patient, coupled with clinical decision
making by a competent health care practitioner. The mo-
tivation, financial circumstances, and preferences of the
gout patient also need to be considered in clinical practice,
and it is incumbent on the treating clinician to weigh the
issues not addressed by this methodology, such as treat-
ment costs, when making management decisions. Last, the
guidelines for gout management presented herein were not
designed to determine eligibility for health care cost cov-
erage by third party payors.
Materials and methods
Utilizing the RAND/UCLA methodology (18), we con-
ducted a systematic review, generated case scenarios, de-
veloped recommendations, and graded the evidence.
Design: RAND/UCLA Appropriateness Method over-
view. The RAND/UCLA method of group consensus was
developed in the 1980s, incorporates both Delphi and
nominal group methods (18), and has been successfully
used to develop other guidelines commissioned by the
ACR. The purpose of this methodology is to reach a con-
sensus among experts, with an understanding that pub-
lished literature may not be adequate to provide sufficient
evidence for day-to-day clinical decision making. The
RAND/UCLA method requires 2 groups of experts: a core
expert panel (CEP) that provides input into case scenario
development, and a task force panel (TFP) that votes on
the case scenarios (1). A systematic review of pertinent
literature was performed concurrently, and a scientific
evidence report was generated. This evidence report was
then given to the TFP, in conjunction with a variety of
clinical scenarios and clinical decision-making questions
of interest for each scenario.
The diverse TFP, totaling 11 people, consisted of rheu-
matologists in a community private practice (CK), a health
maintenance organization practice (GL), and a Veterans
Affairs practice (GK); a rheumatology physician–scientist
inflammation researcher (BR); a rheumatologist with ex-
pertise in clinical pharmacology (DEF); a rheumatologist
gout expert that is an Internal Medicine Residency Direc-
tor (NLE); a rheumatologist gout expert that is a Chair of
Internal Medicine (BM); 2 primary care internal medicine
physicians (DJ, SAY); a nephrologist (VN); and a patient
representative (SK) (1). There were 2 rounds of ratings, the
first anonymous, with the members of the TFP instructed
to rank each potential element of the guidelines on a
risk/benefit Likert scale ranging from 1–9, followed by a
face-to-face group discussion with revoting. A vote of 1–3
on the Likert scale was scored as inappropriate, where
risks clearly outweigh the benefits; a vote of 4–6 was
scored as uncertain (“lack of consensus”), where the risk/
benefit ratio is uncertain; and a vote of 7–9 was scored as
appropriate, where benefits clearly outweigh the risks.
Case scenarios were translated into recommendations,
where the median voting scores were 7–9 on the Likert
scale (“appropriate”), and if there was no significant dis-
agreement, defined as no more than one-third of the TFP
voting below the Likert scale level of 7 in the question. The
final rating was done anonymously in a 2-day face-to-face
meeting led by an experienced internal medicine physi-
cian moderator (NW).
Systematic review. PubMed and the Cochrane Central
Register of Controlled Trials (CENTRAL) were searched to
find all articles on gout with the help of an experienced
librarian. PubMed is a database of medical literature from
the 1950s to the present. CENTRAL includes references
from PubMed, Embase, and the Cochrane Review Groups’
specialized registers of controlled trials and hand search
results. We used search terminology (hedge) based on the
Cochrane Highly Sensitive Search Strategy for identifying
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randomized trials. The hedge was expanded to include
articles discussing research design, cohort, case–control,
and cross-sectional studies. Limits added to the hedge
include English language and the exclusion of “animal
only” studies. The searches for all 4 domains were con-
ducted simultaneously and therefore included terms for
hyperuricemia and other gout-related issues. Conducted
on September 25, 2010, the search retrieved 5,830 articles
from PubMed and CENTRAL. The review was divided into
3 stages: titles, abstracts from manuscripts, and entire
manuscripts. At each stage, each title, abstract, or manu-
script was included or excluded using prespecified rules,
as described (1). Of the 5,830 titles, 192 duplicate titles
and 82 non-English titles were excluded, with an addi-
tional 3,729 titles excluded based on exclusion criteria,
leaving 1,827 titles, of which another 1,699 were excluded
in the abstract phase. A total of 128 manuscripts remained
that were further categorized into pharmacologic and non-
pharmacologic studies (1). Subsequently, we updated our
systematic review by repeating the search with the same
criteria to include any articles that were published be-
tween September 25, 2010 and March 31, 2011, and we
hand searched recent meeting abstracts from the ACR and
EULAR for any randomized controlled trials that were yet
to be published. The supplemental search resulted in 4
additional manuscripts and 5 meeting abstracts on phar-
macologic agents, some of which were subsequently pub-
lished and then reevaluated for evidence grade. Finally,
there were 41 manuscripts on nonpharmacologic modali-
ties (such as diet, alcohol, exercise, etc.) that included both
retrospective and prospective studies, but all were ex-
cluded, since none were randomized controlled studies on
interventions in gout patients. There were 87 manuscripts
on pharmacologic agents for the treatment of patients with
gout. Of these, 47 were randomized controlled trials and
included in the evidence report, whereas the remaining 40
uncontrolled trials were excluded. A total of 21 manu-
scripts on ULT were separately addressed (1).
For this article (part 2 of the guidelines), a total of 30
manuscripts and 5 meeting abstracts were assessed, with
26 manuscripts and 2 meeting abstracts on acute gout and
4 manuscripts and 3 meeting abstracts on prophylaxis
included in the evidence report and evaluated by the TFP.
Case scenarios. Through an interactive, iterative pro-
cess, the CEP developed unique case scenarios of acute
gouty attacks with varied treatment options, and the type
of attack by severity, duration, and extent of the attack.
The objective was to represent a broad spectrum of attacks
that a clinician might see in a busy practice. For the case
scenarios, the severity of acute gout differed based on
self-reported worst pain on a 0–10 visual analog scale
(VAS) (19,20). Pain 4 was considered mild, 5–6 was
considered moderate, and 7 was considered severe
(19,20). Case scenarios also varied by duration of the acute
gout attack; we divided this into early (12 hours), well
established (12–36 hours), and late (36 hours). Case sce-
narios also varied in the number of active joints involved:
1 or a few small joints, 1 or 2 large joints (ankle, knee,
wrist, elbow, hip, or shoulder), and polyarticular involve-
ment (defined as either acute arthritis involving 3 separate
large joints, or acute arthritis of 4 or more joints, with
arthritis involving more than 1 “region” of joints). Joint
regions were defined as: forefoot (metatarsal joints and
toes), midfoot (tarsal joints), ankle/hindfoot, knee, hip,
fingers, wrist, elbow, shoulder, or other (Figure 1). The
management strategies presented were developed for case
scenarios involving gouty arthritis, but the intent was that
acute bursal inflammation due to gout (e.g., in the prepa-
tellar or olecranon bursa) and small joint involvement
would have comparable recommendations for overall
management strategies.
Developing recommendations from votes by the TFP
and grading the evidence. A priori recommendations
were derived from only positive results (median Likert
score 7). In the text below, all recommendations derived
from TFP votes are denoted by an accompanying evi-
dence grade. In addition to TFP vote results, the panel
provided some statements based on discussion (not votes).
Such statements are specifically described as discus-
sion items (rather than TFP-voted recommendations) in
the Results. We also comment on specific circumstances
where the TFP did not vote a particularly important clin-
ical decision-making item as appropriate (i.e., the median
Likert score was 6 or there was a wide dispersion of votes
despite a median score of 7). Samples of voting scenarios
and results are shown in Supplemental Figure 1 (available
in the online version of this article at http://onlinelibrary.
wiley.com/journal/10.1002/(ISSN)2151-4658).
The level of evidence supporting each recommendation
was ranked based on previous methods used by the Amer-
ican College of Cardiology (21) and applied to other recent
ACR recommendations (22,23): level A grading was as-
signed to recommendations supported by more than 1
randomized clinical trial, or 1 or more meta-analyses; level
B grading was assigned to the recommendations derived
from a single randomized trial, or nonrandomized studies;
and level C grading was assigned to consensus opinion of
experts, case studies, or standard of care.
Managing perceived potential conflict of interest (COI).
Potential COI was managed in a prospective and struc-
tured manner (1). All of the participants intellectually
involved in the project, whether authors or not, were re-
quired to fully disclose their relationships with any of the
companies with a material interest in gout, listed in Sup-
plemental Appendix A (available in the online version
of this article at http://onlinelibrary.wiley.com/journal/
10.1002/(ISSN)2151-4658). Disclosures were identified
at the start of the project and updated every 6 months. A
summary listing of all perceived potential COI is available
in Supplemental Appendix A (available in the online
version of this article at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)2151-4658).
Based on the policies of the ACR, no more than 49% of
the project participants were permitted to have COI at any
given time, and a majority of the TFP was required to have
no perceived potential COI. It was further required that the
project principal investigator (JDF) remain without per-
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ceived potential COI during the guideline development
process, and for an additional 12 months afterward.
Results
General principles for treatment of the acute attack of
gouty arthritis (“acute gout” management). Figure 2 sum-
marizes the overall recommendations on treatment of an
acute gouty arthritis attack. The TFP recommended that an
acute gouty arthritis attack should be treated with phar-
macologic therapy (evidence C), and that treatment should
be preferentially initiated within 24 hours of onset of an
acute gout attack (evidence C). The latter recommendation
was based on consensus that early treatment leads to better
patient-reported outcomes. The TFP also recommended
continuing established pharmacologic ULT without inter-
ruption during an acute attack of gout (evidence C), i.e., do
not stop ULT therapy during an acute attack. The TFP also
recommended patient education, not simply on dietary
and other triggers of acute gout attacks, but also providing
the patients with instruction so that they can initiate treat-
ment upon signs and symptoms of an acute gout attack,
without the need to consult their health care practitioner
for each attack (evidence B) (24). Moreover, fundamental
patient education includes discussion that gout is caused
by body excess of uric acid, and that only effective ULT is
potentially “curative” (evidence B) (24).
Initial pharmacologic treatment of the acute attack of
gouty arthritis. The TFP recommended that the choice of
pharmacologic agent should be based upon severity of
pain and the number of joints involved (Figure 2). For
attacks of mild/moderate gout severity (6 of 10 on a 0–10
pain VAS) particularly those involving 1 or a few small
joints or 1 or 2 large joints, the TFP recommended that
initiating monotherapy was appropriate, with recom-
mended options being oral nonsteroidal antiinflammatory
drugs (NSAIDs), systemic corticosteroids, or oral colchi-
cine (evidence A for all therapeutic categories) (25–28)
(Figure 2). The TFP also voted that combination therapy
was an appropriate option to consider when the acute gout
attack was characterized by severe pain, particularly in an
acute polyarticular gout attack or an attack involving 1–2
large joints (evidence C) (Figure 2). The TFP did not rank
one therapeutic class over another. Therefore, it is at the
discretion of the prescribing physicians to choose the most
appropriate monotherapy based on the patient’s prefer-
ence, prior response to pharmacologic therapy for an acute
gout attack, and associated comorbidities. Recommenda-
tions for appropriate combination therapy options are
highlighted in Table 1 and discussed below. The TFP did
not vote on case scenarios for specific renal or hepatic
function impairment–adjusted dosing and individual con-
traindications or drug–drug interactions with pharmaco-
logic therapies (29–31).
Figure 1. Case scenarios for defining acute gouty arthritis attack features. These case scenarios were generated by the core expert panel,
and therapeutic decision-making options for these scenarios were voted on by the task force panel.
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Figure 2. Overview of management of an acute gout attack. This algorithm summarizes the recommendations by the task force panel on
the overall approach to management of an acute attack of gouty arthritis, with further details, as expanded in other figures and tables,
referenced in the figure and discussed in the text. ULT  urate-lowering therapy; NSAID  nonsteroidal antiinflammatory drug; COX-2 
cyclooxygenase 2; GI  gastrointestinal; IL-1  interleukin-1.
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NSAIDs. For NSAIDs, the TFP recommended full dos-
ing at either the Food and Drug Administration (FDA)– or
European Medical Agency–approved antiinflammatory/
analgesic doses used for the treatment of acute pain and/
or treatment of acute gout (evidence A–C) (27,28,32–34)
(Figure 3A). The FDA has approved naproxen (evidence A)
(34,35), indomethacin (evidence A) (27,28,32,33), and
sulindac (evidence B) (36) for the treatment of acute gout.
However, analgesic and antiinflammatory doses of other
NSAIDs may be as effective (evidence B and C). For cyclo-
oxygenase 2 (COX-2) inhibitors, as an option in patients
with gastrointestinal contraindications or intolerance to
NSAIDs, published randomized controlled trials support
the efficacy of etoricoxib (evidence A) and lumiracoxib
(evidence B) (25,37,38), but these agents are not available
in the US, and lumiracoxib has been withdrawn from use
in several countries due to hepatotoxicity. A randomized
controlled trial of a single comparison of celecoxib versus
indomethacin (39) suggested effectiveness of a high-dose
celecoxib regimen (800 mg once, followed by 400 mg on
day 1, then 400 mg twice daily for a week) in acute gout.
The TFP recommended this celecoxib regimen as an op-
tion for acute gout in carefully selected patients with con-
traindications or intolerance to NSAIDs (evidence B),
keeping in mind that the risk/benefit ratio is not yet clear
for celecoxib in acute gout.
The TFP did not reach a consensus to preferentially
recommend any one specific NSAID as first-line treatment.
The TFP did recommend continuing the initial NSAID
inhibitor treatment regimen at the full dose (if appropriate)
until the acute gouty attack completely resolved (evidence
C). The option to taper the dose in patients with multiple
comorbidities/hepatic or renal impairment was reinforced
by the TFP, without specific TFP voting or more prescrip-
tive guidance. Last, there was no TFP consensus on the use
of intramuscular ketorolac or topical NSAIDs for the treat-
ment of acute gout.
Colchicine. The TFP recommended oral colchicine as
one of the appropriate primary modality options to treat
acute gout, but only for gout attacks where the onset was
no greater than 36 hours prior to treatment initiation (ev-
idence C) (Figure 3B). The TFP recommended that acute
gout can be treated with a loading dose of 1.2 mg of
colchicine followed by 0.6 mg 1 hour later (evidence B)
(10), and this regimen can then be followed by gout attack
prophylaxis dosing 0.6 mg once or twice daily (unless dose
adjustment is required) 12 hours later, until the gout attack
resolves (evidence C) (26). For countries where 1.0 mg or
0.5 mg rather than 0.6 mg tablets of colchicine are avail-
able, the TFP recommended, as appropriate, 1.0 mg col-
chicine as the loading dose, followed by 0.5 mg 1 hour
later, and then followed, as needed, after 12 hours, by
continued colchicine (up to 0.5 mg 3 times daily) until the
acute attack resolves (evidence C). In doing so, the TFP
rationale was informed by pharmacokinetics of the low-
dose colchicine regimen, where the exposure to the drug
in plasma becomes markedly reduced 12 hours after
administration in healthy volunteers (26). The TFP also
evaluated prior EULAR recommendations on a colchicine
dosing regimen for acute gout (0.5 mg 3 times daily) and
the BSR-recommended maximum dosage for acute gout of
2 mg colchicine per day (10,12).
The algorithm in Figure 3B outlines recommendations
for colchicine based on FDA labeling and TFP delibera-
tions and votes, including specific recommendations for
patients already receiving colchicine acute gout attack pro-
phylaxis. For more specific prescriptive guidance, practi-
tioners should consult the FDA-approved drug labeling,
including recommended dosing reduction in moderate to
severe chronic kidney disease (CKD) (40,41), and colchi-
cine dose reduction (or avoidance of colchicine use) with
drug interactions with moderate to high potency inhibitors
of cytochrome P450 3A4 and of P-glycoprotein; major col-
chicine drug interactions include those with clarithromy-
cin, erythromycin, cyclosporine, and disulfiram (30,31).
Last, the TFP did not vote on use of intravenous colchi-
cine, since the formulation is no longer available in the
US, due to misuse and associated severe toxicity.
Systemic and intraarticular corticosteroids and adre-
nocorticotropic hormone (ACTH). When selecting corti-
costeroids as the initial therapy, the TFP recommended to
first consider the number of joints with active arthritis. For
involvement of 1 or 2 joints, the TFP recommended the use
of oral corticosteroids (evidence B); the TFP additionally
recommended the option of intraarticular corticosteroids
for acute gout of 1 or 2 large joints (evidence B) (42) (Figure
3C). For intraarticular corticosteroid therapy in acute
gouty arthritis, it was recommended that dosing be based
on the size of the involved joint(s), and that this modality
could be used in combination (Table 1) with oral cortico-
steroids, NSAIDs, or colchicine (evidence B) (42). Specific
doses for intraarticular corticosteroid therapy in specific
joints were not considered during TFP voting.
Where intraarticular joint injection is impractical (e.g.,
polyarticular joint involvement, patient preference, or in-
jection of the involved joint site is not in the scope of the
provider’s usual practice), the TFP recommended oral cor-
Table 1. Task force panel (TFP) recommendations for
combination therapy approach to acute gouty arthritis
Initial combination therapy is an appropriate option
for an acute, severe gout attack, particularly with
involvement of multiple large joints or polyarticular
arthritis (evidence C)
Acceptable combination therapy approaches include
the initial simultaneous use of full doses (or, where
appropriate, prophylaxis doses) of either: 1) colchicine
and nonsteroidal antiinflammatory drugs (NSAIDs),
2) oral corticosteroids and colchicine, or 3) intra-
articular steroids with all other modalities (evidence C)
For patients not responding adequately to initial
pharmacologic monotherapy, adding a second
appropriate agent is an acceptable option (evidence C)*
The TFP was not asked to vote on use of NSAIDs and
systemic corticosteroids in combination, given core
expert panel concerns about synergistic gastrointestinal
tract toxicity
* Assumes that the initial diagnosis of acute gout was correct, and
that the lack of adequate response of acute gout was to an appro-
priate first-line therapy option.
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ticosteroids, prednisone, or prednisolone at a starting dos-
age of at least 0.5 mg/kg per day for 5–10 days, followed by
discontinuation (evidence A) (28,43), or alternately, 2–5
days at the full dose, followed by tapering for 7–10 days,
and then discontinuation (evidence C). Acknowledging
current prevalence of usage, the TFP recommended, as an
Figure 3. Recommendations for the individual pharmacologic monotherapy options for an acute gouty arthritis attack. The figure is
separated into distinct parts that schematize use of the first-line therapy options (A, nonsteroidal antiinflammatory drugs [NSAIDs],
B, colchicine, and C, corticosteroids), and specific recommendations by the task force panel (TFP). COX-2  cyclooxygenase 2; FDA 
Food and Drug Administration; EMA  European Medical Agency; EULAR  European League Against Rheumatism; IM  intramuscular.
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appropriate option according to provider and patient pref-
erence, the use of an oral methylprednisolone dose pack
for initial treatment of an acute attack of gout (evidence C).
The TFP also recommended, as appropriate in each case
scenario, an alternative regimen of intramuscular single-
dose (60 mg) triamcinolone acetonide, followed by oral
prednisone or prednisolone (evidence C). However, there
was no consensus by the TFP on the use of intramuscular
triamcinolone acetonide as monotherapy. Last, the TFP
vote also did not reach a consensus on use of ACTH
(evidence A) for acute gout in patients able to take medi-
cations orally, but did consider ACTH in separate voting,
as described below, for patients unable to take oral anti-
inflammatory medications.
Initial combination therapy for acute gout. For patients
with severe acute gout attack (7 of 10 on a 0–10 pain
VAS) and patients with an acute polyarthritis or involve-
ment of more than 1 large joint, the TFP recommended, as
an appropriate option, the initial simultaneous use of full
doses (or, where appropriate, a full dose of 1 agent and
prophylaxis dosing of the other) of 2 of the pharmacologic
modalities recommended above. Specifically, the TFP rec-
ommended the option to use combinations of colchicine
and NSAIDs, oral corticosteroids and colchicine, or intra-
articular steroids with any of the other modalities (evi-
dence C). The TFP was not asked by the CEP to vote on use
of NSAIDs and systemic corticosteroids in combination,
given CEP concerns about synergistic gastrointestinal tract
toxicity of that drug combination.
Inadequate response of an acute gout attack to initial
therapy. There is a lack of a uniform definition of an
inadequate response to the initial pharmacologic therapy
for an acute attack of gouty arthritis (2,26,44). Clinical
trials in acute gout have defined variable primary end
points for therapeutic response, such as percent improve-
ment in pain on a Likert scale or VAS. To define inade-
quate response for scenarios in this section, the CEP asked
the TFP to vote on various percent improvement defini-
tions at time points such as 24, 48, or 72 hours. The TFP
voted that the following criteria would define an inade-
quate response of acute gout to pharmacologic therapy in
case scenarios: either 20% improvement in pain score
within 24 hours or 50% improvement in pain score 24
hours after initiating pharmacologic therapy.
For the scenario of a patient with an acute attack of
gouty arthritis not responding adequately to initial phar-
macologic monotherapy, the TFP advised, without a spe-
cific vote, that alternative diagnoses to gout should be
considered (Figure 2 and Table 1). For patients not re-
sponding to initial therapy, the TFP also recommended
switching to another monotherapy recommended above
(evidence C) or adding a second recommended agent (ev-
idence C). Use of a biologic interleukin-1 (IL-1) inhibitor
(anakinra 100 mg subcutaneously daily for 3 consecutive
Figure 4. Acute gouty arthritis attack management in the nothing by mouth (NPO) patient. The figure schematizes options for management
of acute gout in the patient unable to take oral antiinflammatory medications, and specific recommendations by the task force panel on
decision making in this setting. ACTH  adrenocorticotropic hormone; IL-1  interleukin-1; IM  intramuscular; NSAID  nonsteroidal
antiinflammatory drug.
ACR Guidelines for Gout Management: Part 2 1455
days; evidence B) (44,45) or canakinumab 150 mg subcu-
taneously (46,47) as an option for severe attacks of acute
gouty arthritis refractory to other agents was graded as
evidence A in the systematic review. Given a lack of ran-
domized studies for anakinra (44,45) and the unclear risk/
benefit ratio and lack of FDA approval for canakinumab
(46,47) at the time this was written, the authors, indepen-
dent of TFP discussion, assessed the role of IL-1 inhibitor
therapy in acute gout as uncertain.
Case scenarios for the nothing by mouth (NPO) patient.
Acute gout attacks are common in the in-hospital setting,
where patients may be NPO due to different surgical and
medical conditions. In such a scenario, the TFP recom-
mended intraarticular injection of corticosteroids for in-
volvement of 1 or 2 joints (with the dose depending on the
size of the joint; evidence B) (42) (Figure 4). The TFP also
recommended, as appropriate options, intravenous or in-
tramuscular methylprednisolone at an initial dose at 0.5–
2.0 mg/kg (evidence B) (48).
The TFP also recommended, as an appropriate alterna-
tive for the NPO patient, subcutaneous synthetic ACTH at
an initial dose of 25–40 IU (evidence A) (49), with repeat
doses as clinically indicated (for either ACTH or intrave-
nous steroid regimens). There was no voting by the TFP on
specific followup ACTH or an intravenous steroid dosing
regimen, given a lack of evidence. In the scenario of the
NPO patient with acute gout, there was no consensus on
the use of intramuscular ketorolac or intramuscular triam-
cinolone acetonide monotherapy. Biologic IL-1 inhibition
therapy remains an FDA-unapproved modality for NPO
patients, without specific past evaluation in this popula-
tion.
Critical drug therapy adverse event considerations in
acute gout. It was not possible to evaluate every permuta-
tion of gout treatment and comorbid disease, given the
constraints of the project. The treating clinician will need
to carefully weigh the complexities of each unique patient.
TFP discussions emphasized that potential drug toxicities
due to comorbidities and drug–drug interactions are con-
siderable in treatment of acute gout (30,31). Some exam-
ples include underlying moderate and severe CKD
(NSAIDs, COX-2 inhibitors, colchicine), congestive heart
failure (NSAIDs, COX-2 inhibitors), peptic ulcer disease
(NSAIDs, COX-2 inhibitors, corticosteroids), anticoagula-
tion or antiplatelet aggregation therapy (NSAIDs), diabetes
mellitus (corticosteroids), ongoing infection or high risk of
infection (corticosteroids), and hepatic disease (NSAIDs,
COX-2 inhibitors, colchicine) (30,31).
Complementary therapies for acute gout attack. The
TFP recommended topical ice application to be an appro-
priate adjunctive measure to 1 or more pharmacologic
therapies for acute gouty arthritis (evidence B) (50). The
TFP voted, as inappropriate, the use of a variety of oral
complementary agents for the treatment of an acute at-
tack (cherry juice or extract, salicylate-rich willow bark
extract, ginger, flaxseed, charcoal, strawberries, black cur-
rant, burdock, sour cream, olive oil, horsetail, pears, or
celery root).
Recommendations for pharmacologic
antiinflammatory prophylaxis of attacks of
acute gout
The TFP recommended pharmacologic antiinflammatory
prophylaxis for all case scenarios of gout where ULT was
initiated, given high gout attack rate frequencies in early
ULT (evidence A) (51–54) (Figure 5). For gout attack pro-
phylaxis, the TFP recommended, as a first-line option, use
of oral colchicine (evidence A) (54,55). The TFP also rec-
ommended, as a first-line option (with a lower evidence
grade than for colchicine), the use of low-dose NSAIDs
(such as naproxen 250 mg orally twice a day), with proton-
pump inhibitor therapy or other effective suppression
therapy for peptic ulcer disease and its complications,
where indicated (evidence C) (54).
In their evaluation of colchicine evidence in gout attack
prophylaxis, the TFP specifically recommended low-dose
colchicine (0.5 mg or 0.6 mg orally once or twice a day,
with dosing further adjusted downward for moderate to
severe renal function impairment and potential drug–drug
interactions) (30) as appropriate for gout attack prophy-
laxis. The TFP did not vote on specific quantitative renal
function impairment–adjusted dosing of oral colchicine.
Since a pharmacokinetic analysis suggesting colchicine
dose should be decreased by 50% below a creatinine clear-
ance of 50 ml/minute is unpublished in peer-review form
(41), specific quantitative colchicine dose adjustment in
CKD is the decision of the treating clinician.
The TFP, in discussion without a specific vote, recog-
nized the evidence that colchicine and low-dose NSAID
prophylaxis fail to prevent all gout attacks in patient
populations after initiation of ULT (51–54). As an alter-
native gout attack prophylaxis strategy in patients with
intolerance or contraindication or refractoriness to both
colchicine and NSAIDs, the TFP recommended use of
low-dosage prednisone or prednisolone (defined here as
10 mg/day) (evidence C). Nevertheless, concerns were
raised in discussion among the TFP and by the other
authors regarding particularly sparse evidence for efficacy
of this low-dose strategy. Given the known risks of pro-
longed use of corticosteroids, the authors urge clinicians to
be particularly attentive in reevaluating the risk/benefit
ratio of continued corticosteroid prophylaxis as the risk of
acute gout attack decreases with time in conjunction with
effective ULT. The TFP voted the use of high daily doses
(i.e., 10 mg daily) of prednisone or prednisolone for gout
attack prophylaxis to be as inappropriate in most case
scenarios, and there was a lack of TFP consensus for more
severe forms of chronic tophaceous gouty arthropathy.
Last, there was a lack of TFP consensus on the risk/benefit
ratio for off-label use of biologic IL-1 inhibition (evidence
A) (56,57) for antiinflammatory gout attack prophylaxis
in patients who previously failed or had intolerance or
contraindications to low doses of colchicine, NSAIDs, and
prednisone or prednisolone for gout attack prophylaxis.
Duration of antiinflammatory prophylaxis of acute gout
attacks. The TFP recommended to continue pharmaco-
logic gout attack prophylaxis if there is any clinical evi-
dence of continuing gout disease activity (such as 1 or
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more tophi detected on physical examination, recent acute
gout attacks, or chronic gouty arthritis), and/or the serum
urate target has not yet been achieved (1). Specifically, the
TFP voted to continue the prophylaxis for the greater of:
1) 6 months’ duration (evidence A) (51,53,54), 2) 3 months
after achieving the target serum urate level for the patient
without tophi detected on physical examination (evidence
B), or 3) 6 months after achieving the target serum urate
Figure 5. Pharmacologic antiinflammatory prophylaxis of gout attacks and its relationship to pharmacologic urate-lowering therapy
(ULT). The figure provides an algorithm for use of antiinflammatory prophylaxis agents to prevent acute gout attacks. The schematic
highlights specific recommendations by the TFP on decision making on the initiation, options, and duration of prophylaxis relative to
pharmacologic ULT therapy, relative to achievement of the treatment objectives of ULT. NSAIDs  nonsteroidal antiinflammatory drugs.
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level, where there has been resolution of tophi previously
detected on physical examination (evidence C) (Figure 5).
Discussion
Acute attacks of gout have a detrimental impact on the
quality of life of the patient due to pain and dysfunction of
affected joints, and acute gout can have a substantial eco-
nomic and societal impact (58–60). Following a system-
atic review of the literature and use of a formal group
assessment process, we provide the first ACR guidelines
for the therapy and antiinflammatory prophylaxis of acute
gout attacks.
The TFP recommended multiple modalities (NSAIDs,
corticosteroids by different routes, and oral colchicine) as
appropriate initial therapeutic options for acute gout at-
tacks. The TFP was informed in part by recent direct
comparison studies suggesting approximate equivalency
of oral systemic corticosteroids with NSAIDs (28,43). Es-
sentially, the TFP concluded, without a specific vote, that
selection of treatment choice is that of the prescribing
clinician, and to be based upon factors including patient
preference, the patient’s previous response to pharmaco-
logic therapies, associated comorbidities and, in the
unique case of colchicine, the time since onset of the acute
gout attack. The dosing adjustments and relative and ab-
solute contraindications for NSAIDs and colchicine due to
associated comorbidities (such as renal and hepatic im-
pairment) and drug interactions were not addressed in
these guidelines. There is published literature addressing
these issues (30,31) such as quality indicators for safe use
of NSAIDs (61–63), including ACR quality indicators for
treatment of gout (64).
The TFP recommended a novel set of strict limitations
on colchicine doses for acute gout, starting with no more
than 1.8 mg over 1 hour in the first 12-hour period of
treatment (evidence B) (26), a paradigm shift from wide-
spread prior use of this drug in clinical practice (10,12),
but in accordance with FDA guidance. Prior EULAR and
BSR recommendations on colchicine dosing for acute gout
(10,12) and colchicine low-dose regimen pharmacokinet-
ics (26) informed the TFP recommendation of low-dose
colchicine (at a maximum of 0.6 mg twice daily) as a
continuation option for an acute gout attack, if started at
least 12 hours following the initial low-dose regimen.
For patients with polyarticular joint involvement and
severe presentations of gout in 1 or 2 large joints, the TFP
recommended, as appropriate, certain first-line combina-
tion therapy approaches. Although there is a lack of pub-
lished randomized controlled trial data to support these
recommendations, a large survey of rheumatologists in the
US has shown that combination therapy for acute gout is
often employed (65).
With respect to antiinflammatory prophylaxis of acute
gout attacks, low-dose colchicine or low-dose NSAIDs
were recommended as acceptable first-line options by the
TFP, with a higher evidence level for colchicine. The use
of low-dose colchicine or an NSAID in gout attack prophy-
laxis is also recommended by EULAR (10). To date, in
small clinical trials, low-dose daily oral colchicine was
effective in preventing acute gout attacks (3,55), with sup-
portive post hoc analyses in ULT trials (54). The efficacy of
low-dose NSAIDs for gout attack prophylaxis also was
described in the febuxostat clinical trial program (54);
however, prophylaxis was not the primary focus of the
trials. Importantly, recent clinical trials of ULT agents
have shown substantial rates of acute gout attacks in the
first 6 months after the initiation of ULT, even when pro-
phylaxis with colchicine 0.6 mg daily or low-dose NSAID
therapy is administered (51–54). It is noteworthy that the
TFP recommended prednisone or prednisolone 10 mg
daily as a second-line option for acute gout prophylaxis,
with the caveat that there is a lack of published robust data
for the use of low-dose oral prednisone for gout prophy-
laxis. More investigation is needed to improve manage-
ment for this clinical problem. Assessment of modulation
of cardiovascular event risks by colchicine prophylaxis or
by NSAIDs (66) in patients with gout would be particularly
informative.
Limitations of the recommendations presented in this
article include that only 30% were based on level A
evidence, with approximately half based on level C evi-
dence; this indicates the need for more studies in the
aspects of gout management considered here. The process
used here was limited by the current trial designs for
assessment of acute gout therapies and prophylaxis of
antiinflammatory pharmacologic agents in gout. For acute
gout studies, most studies were on NSAIDs and involved
an active comparator and noninferiority trial design. How-
ever, the majority of these studies failed to provide a
noninferiority margin, which needs to be defined a priori
to assess the validity of these trials. Although the majority
of studies assessed pain as the primary outcome for the
acute gout trials, there is a lack of a single uniform measure
that precludes meta-analysis. Furthermore, there is a lack
of consensus on what time period after initiation of ther-
apy constitutes a primary response, since trials ranged
from a few hours to 10 days. With the exception of recent
analyses of biologic IL-1 inhibitors (56,57), there was a
lack of robust clinical trials of gout attack prophylaxis
using antiinflammatory pharmacologic agents. Also, the
primary measure in these trials is the recurrence of self-
reported acute gout attacks, an outcome that has not been
validated using Outcome Measures in Rheumatology cri-
teria (67). Efforts are underway to precisely define acute
gout attack in gout clinical trials (68). Last, the RAND/
UCLA methodology did not address important societal
and patient preference issues on treatment costs and cost-
effectiveness comparisons between medication choices for
acute gout and pharmacologic prophylaxis of acute gout
attacks. This is already a pressing question with respect to
use of agents, including colchicine and COX-2 selective
inhibitors, and would be expected to emerge as a larger
issue if biologic IL-1 inhibitors, in late-stage clinical de-
velopment after phase III studies at the time this was
written, obtain regulatory approval for acute gout treat-
ment and prophylaxis.
In summary, these guidelines, the first from the ACR
for the management and antiinflammatory prophylaxis
of acute attacks of gouty arthritis, have been developed
to provide recommendations to clinicians treating pati-
ents with gout. The ACR plans to update these guide-
lines to capture future treatments or advances in the
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management and prophylaxis of acute gout, and as the
risk/benefit ratios of emerging therapies are further inves-
tigated.
Addendum. Therapies that were approved after the
original literature review, or diet and lifestyle measures
studied after the original literature review, are not in-
cluded in these recommendations.
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